Predictive biomarkers for tumor immune checkpoint blockade

The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Mengting, Wang, Jing, He, Wenting, Wang, Yanling, Pan, Hongming, Li, Da, Zhang, Hongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190817/
https://www.ncbi.nlm.nih.gov/pubmed/30349382
http://dx.doi.org/10.2147/CMAR.S179680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190817/
https://www.ncbi.nlm.nih.gov/pubmed/30349382
http://dx.doi.org/10.2147/CMAR.S179680

Ejemplares similares